Barclays PLC Has $264,000 Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP)

Barclays PLC increased its position in shares of Rapport Therapeutics (NASDAQ:RAPP) by 36.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,863 shares of the company’s stock after acquiring an additional 3,463 shares during the quarter. Barclays PLC’s holdings in Rapport Therapeutics were worth $264,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Values First Advisors Inc. acquired a new position in shares of Rapport Therapeutics during the third quarter valued at $31,000. BNP Paribas Financial Markets acquired a new position in shares of Rapport Therapeutics during the third quarter valued at $34,000. The Manufacturers Life Insurance Company lifted its stake in shares of Rapport Therapeutics by 2.4% during the third quarter. The Manufacturers Life Insurance Company now owns 77,344 shares of the company’s stock valued at $1,584,000 after acquiring an additional 1,828 shares during the period. SG Americas Securities LLC bought a new position in Rapport Therapeutics during the third quarter worth about $101,000. Finally, Sandia Investment Management LP acquired a new position in shares of Rapport Therapeutics during the 2nd quarter worth about $116,000.

Rapport Therapeutics Price Performance

Shares of RAPP stock opened at $19.48 on Monday. The company has a 50-day moving average of $21.51. Rapport Therapeutics has a one year low of $16.55 and a one year high of $29.74.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.